[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tangram Therapeutics Plc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100625826",false,"NCT07427680","Study of TGM-312-SC01 in Healthy Participants and Adults With MASH","RESTORE-MASH: A Phase 1\u002F2 Randomized, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of TGM-312-SC01 in Healthy Participants and Adults With MASH","Inclusion Criteria:\n\n* Adults aged 18 to 70 years who are able to provide written informed consent.\n* Medically suitable for study participation based on protocol-defined assessments.\n* For the disease cohort, participants with clinical features consistent with metabolic dysfunction-associated steatohepatitis, as defined in the protocol.\n\nExclusion Criteria:\n\n* Clinically significant medical conditions, laboratory abnormalities, or other findings that, in the opinion of the investigator, could increase risk, interfere with study participation, or confound interpretation of study results.\n* Recent participation in another investigational study.\n* Use of medications that are prohibited by the protocol.\n* Any other condition that would make the individual unsuitable for study participation as determined by the investigator.",true,"ALL","18 Years","70 Years",{"count":20,"type":21},99,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH).",[28,29],"Healthy Participants","MASH - Metabolic Dysfunction-Associated Steatohepatitis","RECRUITING","2026-05-18",{"date":33,"type":34},"2026-05-19","ACTUAL",{"date":36,"type":34},"2026-03-03",{"date":38,"type":21},"2028-06",{"name":40,"class":41},"Tangram Therapeutics Plc","INDUSTRY",""]